Primary coenzyme Q10 (CoQ 10
INTRODUCTION
Coenzyme Q (ubiquinone; CoQ) is a lipophilic redox molecule, essential for diverse cellular roles, including as an electron carrier, regulator of transition pores, and a substrate for pyrimidine nucleotide synthesis.
It also acts as an antioxidant and a modulator of fatty acid -oxidation.
Indeed, it links FAO to mitochondrial respiratory chain through electron transfer flavoprotein (ETF) and ETF:ubiquinone oxidoreductase (ETFQO). Following the characterization of their yeast counterparts, the human Coenzyme Q gene family was shown to include over 13 genes involved in the biosynthesis of CoQ 10 ; at least eight of these are associated with human disorders .
Diseases of CoQ 10 deficiency have been reported in over 100 individuals worldwide. Their heterogeneous clinical features are consistent with one of five major phenotypes (Quinzii, Emmanuele, & Hirano, 2014) : (1) Encephalopathy, associated with mitochondrial myopathy and myoglobinuria (Boitier et al., 1998; Ogasahara, Engel, Frens, & Mack, 1989; Salviati et al., 2012; Sobreira et al., 1997) ; (2) severe infantile disease with multi-systemic involvement (Desbats et al., 2015; Dinwiddie et al., 2013; Quinzii et al., 2006; Rotig et al., 2000) ; (3) ataxia with cerebellar atrophy, the most common form, variably associated with seizures, cognitive impairment, muscle weakness, neuropathy, and hypogonadism (Gironi et al., 2004; Lagier-Tourenne et al., 2008; Musumeci et al., 2001 ); (4) nephropathy, with or without sensory hearing loss (Ashraf et al., 2013; Diomedi-Camassei et al., 2007; Heeringa et al., 2011; McCarthy et al., 2013) ; and (5) isolated myopathy (Gempel et al., 2007; Horvath et al., 2006; Lalani et al., 2005) . In the past decade, next-generation sequencing techniques have facilitated molecular diagnosis of these patients, enabling further elucidation of genotype-phenotype correlations (Yubero et al., 2014) . Of the numerous human mitochondrial disorders, CoQ 10 deficiency is considered the only currently treatable disorder, since patients often respond to oral CoQ 10 supplementation (DiMauro, Quinzii, & Hirano, 2007; Garrido-Maraver et al., 2014) .
While several genes in the CoQ 10 biosynthesis pathway have been implicated in primary CoQ 10 deficiency (MIM# 607426) , no human phenotype attributable to COQ5 mutations has been described. Coq5
is an important enzyme that catalyzes the only C-methylation step involved in the synthesis of Coq 10 in yeast and mammalian cells (Baba et al., 2004; Barkovich et al., 1997; Nguyen et al., 2014) , and has been
shown to assemble with a multi-subunit Coq polypeptide complex (He, Xie, Allan, Tran, & Clarke, 2014) . It is expressed in multiple tissues but highest in liver, lung, placenta, and skeletal muscle.
We report for the first time patients with encephalomyopathy, cerebellar ataxia, and additional findings in a multiplex nonconsanguineous family with CoQ10 deficiency due to a biallelic duplication in COQ5.
METHODS

Patients
Patients and family members were enrolled in NIH protocol 76-HG- 
Single-nucleotide polymorphism arrays
Single-nucleotide polymorphism (SNP) genotyping was performed on genomic DNA with the use of the HumanOmniExpress DNA Analysis BeadChip (Illumina, San Diego, CA, USA). SNPs were analyzed using GenomeStudio software (Illumina) (Peiffer et al., 2006; Steemers & Gunderson, 2007) .
Next-generation sequencing
For whole-exome sequencing (WES), the library preparation method was performed using the SureSelect Human All-Exon System version 1.0 (Agilent Technologies, Santa Clara, CA, USA). Sequencing was performed with the use of the Genome Analyzer IIx sequencer (Illumina).
For whole-genome sequencing (WGS), the library preparation method was performed using the Illumina TruSeq Nano. Sequencing was performed with the Illumina HiSeq X Ten sequencer (Illumina). Variants were filtered and visualized using the graphical software tool VarSifter v1.5 (Teer, Green, Mullikin, & Biesecker, 2012).
Biochemistry
Blood samples were drawn at baseline and at different time points during CoQ supplementation into acid citrate dextrose tubes and were submitted for CoQ 10 analyte measurement in leukocytes by a clinical laboratory (https://mnglabs.com). A piece of a muscle biopsy from one of the affected patients was flash-frozen and subjected to CoQ 10 measurement by a clinical laboratory using high performance liquid chromatography (https://www.rgbmgl.org). Other pieces were fixed in formalin and embedded in paraffin for cytochrome c oxidase staining.
PCR and Sanger sequencing
For PCR and dideoxy sequencing, specific primers were designed (sequences available upon request) to amplify the regions of interest. Direct sequencing of the PCR products was performed using 
Copy number analysis
Copy number (CN) analysis by quantitative PCR (qPCR) was performed using 3 TaqMan probes in the duplicating area (Hs00355860_cn, Hs06353017_cn and Hs00837086_cn), 2 flanking the duplicated area (Hs01474184_cn and Hs07018271_cn) and an endogenous control probe in the GAPDH gene (Hs00894322_cn). All the probes were purchased from Applied Biosystems (Foster City, CA). All the qPCR experiments were performed in triplicate as described (Vilboux et al., 2011) on an ABI PRISM 7900 HT Sequence Detection System (Applied Biosystems). The comparative Ct method was used to determine the CN (Livak & Schmittgen, 2001 ).
Analysis of COQ5 expression in fibroblasts
Fibroblasts from III.6 were grown as explants from skin biopsies in 10% FBS in DMEM (Malicdan et al., 2015 with the comparative CT method as described (Livak & Schmittgen, 2001 Nuclear and cytosolic fractions were prepared using the rapid, efficient, and practical (REAP) method (Suzuki, Bose, Leong-Quong, Fujita, & Riabowol, 2010) . Cells were scraped into 1× PBS, pelleted, and lysed in 0.1% NP40-PBS buffer. Samples were then pelleted briefly and the supernatant was taken as the cytosolic fraction. The pellet was resuspended in 0.1% NP40-PBS buffer, spun down once more, and the resulting nuclear pellet was dissolved in 1× Laemmli Sample Buffer (Bio-Rad, Hercules, CA, USA) and used as the nuclear fraction. Samples were electrophoresed as above.
Oxygen consumption measurement in human fibroblasts
Human fibroblasts were measured for the mitochondrial oxygen consumption rate (OCR) by using the Seahorse XF24 Instrument (Seahorse Bioscience, Billerica, MD). Wild-type control and patient fibroblast cells were plated on XF-24 plates 48 hr before the analysis at 20,000 cells per well and grown in DMEM which contained 25 mM glucose, 10% FBS and 1% MEM Non-Essential amino acid at 37 • C with 5% CO 2 . Twenty minutes prior to the analysis, the culture medium was replaced by unbuffered DMEM XF Base medium (Seahorse Bioscience) at pH 7.4 contained with 5 mM glucose, 2 mM GlutaMAX, and 1 mM sodium pyruvate, and the plates were incubated at 37 • C in a CO 2 -free incubator. The mitochondrial OCR was measured under the following conditions: (1) basal, and after the addition of (2) 1.25 M oligomycin, (3) 
Muscle biopsy and biochemical measurements
Needle muscle biopsy was processed for muscle histochemistry as previously described (Mozaffar & Pestronk, 2000; Pestronk, Kaiser, & Brooke, 1992) (Brooke & Kaiser, 1970) . A total of 197 fibers were counted and the type 2C fiber frequency was defined as the percentage of 2C fibers in a random cross-section photomicrograph field. Analysis of CoQ 10 levels in the muscle was performed by a clinical diagnostic laboratory. For measuring the activity of individual mitochondrial complexes, we followed our published methods (Kirby, Thorburn, Turnbull, & Taylor, 2007; Taylor, Birch-Machin, Bartlett, & Turnbull, 1993) .
Clinical scoring
Treatment with CoQ supplementation (Ubiquinol; 15 mg/kg/d divided into three dosages) was given to the three affected patients for a period of 6 months. We used the ICARS (The International Cooperative Ataxia Rating Scale) (Trouillas et al., 1997) to assess the effect of CoQ supplementation on the various aspects of their cerebellar dysfunction by performing the test at baseline, and 3 and 6 months after initiation of treatment. Due to technical issues, the treatment was stopped by the parents two weeks before the assessment at 6 months.
The ICARS is an outcome measure that was created in 1997 by the Committee of the World Federation of Neurology with the goal of standardizing the quantification of impairment due to cerebellar ataxia.
The scale is scored out of 100 with 19 items and four subscales of postural and gait disturbances, limb ataxia, dysarthria, and oculomotor disorders. Higher scores indicate higher levels of impairment.
RESULTS
Patients
Three female siblings ( Figure 1A ), born to non-consanguineous parents of Iraqi-Jewish descent, presented to our center with varying degrees of cerebellar ataxia, encephalopathy, generalized tonic-clonic seizures, and developmental delay. The proband (III.4), the fourth of seven children, presented in early childhood with short stature and moderate delay in motor and cognitive milestones, followed by nonprogressive cerebellar ataxia, dysarthria, mild-moderate cognitive disability, and behavioral problems including impulsivity, short attention span and oppositional characteristics. At approximately 12 years of age, she had myoclonic jerks which were more noticeable during voluntary motor movements. At the age of 17 years, she experienced several generalized tonic-clonic seizures. Epilepsy and myoclonus were well controlled by valproic acid combined with low dose clonazepam.
On physical examination, the patient showed no dysmorphic features.
Her head circumference was 54.5 cm (35th percentile), and her height was 150 cm (−2 standard deviations). She had mild horizontal nystagmus, slow saccades with saccadic pursuit and apraxic gaze, normal fundoscopy, dysarthric cerebellar speech, dysmetria in finger-to-nose test, a mild postural and intention tremor, ataxic gait and inability to perform tandem walking. She also showed mild lower limb spasticity with brisk tendon joint reflexes and negative Babinski sign. (requiring special school only at high school). In her 20s, the patient had myoclonic jerks followed by a single generalized tonic-clonic seizure at the age of 22 years; there was no seizure recurrence on low dose valproic acid, which was later replaced by lamotrigine. The patient gave birth to a healthy baby with no signs of deterioration during her pregnancy. Upon physical examination, she showed mild gait ataxia with inability to perform tandem walking, mild dysmetria and oculomotor apraxia, and horizontal nystagmus. A brain MRI showed mild cerebellar atrophy and EEG showed infrequent generalized PSW discharges.
The youngest of the affected siblings, III.6, exhibited mild motor delay followed by mild learning difficulties in school, characterized by slow response rate, relatively poor verbal skills and poor writing. She was first examined at the age of 14 years, when mild cerebellar ataxia with abnormal tandem walking were identified, as well as brisk deep tendon reflexes, negative Babinski, no tremor or dysmetria but mild cerebellar dysarthria and horizontal nystagmus with hypometric saccades.
Next-generation sequencing identifies duplication in COQ5
Because of the Iraqi-Jewish origin of both parents, a homozygote recessive mode of inheritance was suspected. A SNP array study, performed on the parents and all the siblings revealed several areas of homozygous regions (Supp . Table S1 ), conforming consanguinity in the family; however, there was one homozygous region, from 118.5- The average number of reads in this region (∼60×) compared with the rest of the region (∼30×) suggested the presence of four copies, that is, a homozygote duplication) ( Figure 1C ).
Sanger sequencing confirmed the breakpoints of this duplication and showed that it was in tandem ( Figure 1C ). This duplication, To investigate the potential effect of this duplication on COQ5, we first measured the mRNA expression level. In patient fibroblasts, qRT-PCR using two different probe sets revealed COQ5 mRNA at a level of only 2%-4% of that in control fibroblasts (Figure 2A ). We then demonstrated reduced COQ5 protein expression in patient fibroblasts by Western blotting ( Figure 2B ). Sequencing of the cDNA demonstrated that part of the 3 ′ UTR has been spliced off and replaced by the duplicated part of the gene (exon 4-7), generating a longer alternative 3 ′ UTR ( Figure 2C ).
COQ 10 levels are reduced in patient's leukocytes and muscle tissue
To determine whether the COQ5 deficiency could affect CoQ 10 synthesis, we examined CoQ 10 levels of affected and unaffected family members. CoQ 10 levels were mildly reduced in all three affected patients (III.3, III.4, and III.6), as compared with their unaffected mother (II.2) ( Figure 3A) . We then collected a muscle specimen from III.4, that showed increased type 2C muscle fibers ( Figure 3B ), which comprised ∼34% of all the myofibers; in comparison, type 2C fibers usually comprise only 0%-6.5% of the total number of fibers in unaffected young women (Staron et al., 2000) . There were no signs of myopathy, ragged red fibers, mitochondrial dysfunction or structural Figure 3B ). CoQ 10 levels obtained from the skeletal muscle biopsy were reduced, confirming primary CoQ 10 deficiency ( Figure 3A ; full blot shown as Supp. Figure S1 ).
Measurement of oxygen consumption and activity of the respiratory complex chain in human fibroblasts
To understand the metabolic effects in the mitochondria due to the COQ5 mutation, we used the Seahorse analyzer to measure the cellular OCR in cultured fibroblasts. The mutation in COQ5 significantly reduced uncoupled respiration compared with normal ( Figure 3C ). Similarly, high-resolution respirometry in fibroblasts showed a reduced uncoupling ratio and increased net routine flux control ratio, consistent with decreased reserve capacity (Supp . Table   S2 ). In addition, the phosphorylation respiratory control ratio was increased, indicating that a higher proportion of oxidative phosphorylation is activated to drive ATP synthesis. We also measured the activity of the individual complexes of the respiratory complex chain including the combined activity of II and III, on mitochondrial fractions isolated from dermal fibroblasts, following our published methods (Kirby et al., 2007; Taylor et al., 1993) . Our analysis showed that there is a measurable defect in Complex II+III activity in the cells, using an assay that relies on endogenous CoQ10 to shuttle electrons from succinate to cytochrome c (Supp . Table S3 ).
Clinical outcome of CoQ 10 supplementation in patients with defects in COQ5
The pre-treatment ICARS scoring was consistent with the relative clinical severity of the disorder for each patient; the more affected patient (III.4) scored 27 out of 100 and the least affected patient (III.6) scored 13 out of 100. After 3 months of CoQ 10 treatment, the scores of all three patients decreased significantly (patient 1: 27-14.5, patient 2:
13-7.5, and patient 3: 23-8.5). In addition, the patients appeared to have a quicker response rate during conversation and better alertness under the CoQ 10 supplementation. A follow-up visit was obtained 6 months after initiation of treatment, and 2 weeks after halting CoQ 10 treatment. Clinical assessment showed slight deterioration in the scoring results compared with the 3-months' assessment rates (patient 1:
−22, patient 2: −8, patient 3: −11) ( Figure 3D ).
DISCUSSION
We describe for the first time primary Our CNV analysis on 92 unaffected Iraqi-Jewish controls may be much higher than anticipated; this could be due to the fact that the samples came from a single area. We approximate the MAF to be 1.5%, indicating that CoQ5 deficiency remains underdiagnosed. The combination of manual or automated CNV analysis and next-generation sequencing can help detecting this new variant and therefore can potentially provide diagnosis to some patients with idiopathic cerebellar ataxia.
Our study defines a new subtype of primary CoQ 10 deficiency due to a loss-of-function mutation in COQ5. We have demonstrated that modest reduction in CoQ 10 levels were present in peripheral blood leukocytes of affected patients while in skeletal muscles CoQ 10 levels were much more reduced. The overall effect on CoQ 10 levels, especially in skeletal muscle tissue, are consistent with the importance of COQ5 in ubiquinone synthesis (Chen, Liu, & Yen, 2013; Yen et al., 2016) , and confirm the finding that destabilization of the COQ5-containing protein complex in human cells reduces CoQ 10 levels (Yen et al., 2016) . It is important to note, however, that although the CoQ 10 levels low, there is still some amount of CoQ 10 produced in leukocytes and muscle. We hypothesize that in the affected individuals in this study, the respiration rate is limited by the number of CoQ 10 molecules within the mitochondrial inner membrane. However, because the defect in the synthesis of CoQ 10 is partial, there is only a 33% reduction the number of CoQ 10 molecules, which can be sufficient to sustain the basal respiration rate in fibroblasts but not the maximum respiration rate.
In addition to the biochemical abnormality of CoQ 10 deficiency, the finding of increased frequency of type 2C fibers in morphologically normal muscle in our proband is also consistent with CoQ 10 deficiency as previously reported (Sommerville, Zaidman, & Pestronk, 2013) , where the increase in the number of type 2C fibers was thought to be due to inhibition of fiber maturation. Type 2C muscle fibers represent immature fibers, as they are abundant in fetal muscle and normally decline to less than 5% of fibers by the age of 1 year (Brooke & Kaiser, 1970) .
Increased type 2C fiber frequency after the age of 1 year occurs in active myopathic disorders with prominent muscle fiber regeneration.
In terms of clinical features, our patients had variable degrees of cerebellar ataxia as their main neurological feature; other neurological symptoms were more variable. The most affected patient had mild to moderate cognitive impairment and a seizure disorder, while the least affected sib functioned in the low-to-normal intelligence range and never had seizures or an abnormal EEG. Cerebellar ataxia with cerebellar atrophy is the most common of the five phenotypes described with primary CoQ 10 deficiency and is found mainly in COQ8 (ADCK3) deficiency, defined also as autosomal recessive cerebellar ataxia 2 (ARCA2), but can also be seen in several secondary CoQ deficiency syndromes (Balreira et al., 2014; Chamova et al., 2012; Maruyama et al., 2014; Quinzii et al., 2005) . The significant cerebellar involvement in both primary and secondary CoQ 10 deficiency conditions may be related to lower content of endogenous CoQ 10 in the cerebellum compared with other brain regions, as demonstrated in the rat (Naini, Lewis, Hirano, & DiMauro, 2003) .
In addition to cerebellar ataxia and atrophy, other features described in CoQ 10 deficiency syndromes include seizure disorder, dystonia, migraines, cognitive disability, and exercise intolerance.
Patients in previous reports and in the current study have not shown extra CNS symptoms or signs, except for occasional exercise intolerance, despite reduced levels of CoQ 10 in other tissues (Lagier-Tourenne et al., 2008; Mignot et al., 2013; Mollet et al., 2008) .
High dose oral supplementation of CoQ 10 has been effective in primary (Ashraf et al., 2013; Doimo et al., 2014; Heeringa et al., 2011; Montini, Malaventura, & Salviati, 2008; Salviati et al., 2005) and secondary CoQ 10 deficiency syndromes (Musumeci et al., 2001; Quinzii et al., 2005) , and in cerebellar ataxia-related syndromes (whether with or without a molecular diagnosis) (Lo et al., 2015; Pineda et al., 2010) .
We started a therapeutic trial in our three affected patients soon after the molecular diagnosis was made, while all were in their 20s. The dosage used was 15 mg/kg/d divided into three doses. Even though our patients' ataxia severity is currently mild to moderate with baseline scores ranging from 13 to 27 out of 100, after 3 months of treatment their scoring was significantly reduced and ranged from 14.5 out of 100 in the most severely affected patient and to 7.5 out of 100 in the least severely affected. Unfortunately, the three sisters stopped their CoQ 10 intake 2 weeks before the second assessment at 6 months. It is possible that the relatively higher score, showing worsening from the previous exam after 6 months of treatment (8-22 out of 100) instead of the expected further improvement, may be attributable to the fact that they did not take the CoQ 10 supplementation for 2 weeks before the second assessment. This assumption is consistent with similar experience with treatment tapering previously reported in the literature (Salviati et al., 2012) . The ICARS score, which is the more detailed scoring system used for ataxia assessment, was used in patients with ADCK3 mutations, and significant improvement in the ataxia score was detected after 3 months of treatment (Montero et al., 2007) , as in our patients. Based on the significant change noticed at three months, we recommended our patients to resume the CoQ 10 treatment in the current dosage, and will even consider increasing the dosage if no side effects are noticed and an attenuation in the clinical response is seen.
Variability of the clinical response to CoQ 10 supplementation in the different syndromes, and within the same syndrome in different cohorts, may be related to therapeutic dosages chosen, the pharmaceutical formulation employed, the severity of the underlying illness and organs involved, the time elapsed from clinical presentation to treatment onset (with significant tissue damage already present in late treated patients), or poor tissue delivery of CoQ 10 into the CNS.
In addition, many other environmental and even epigenetic factors likely modulate the response to treatment (Acosta et al., 2016; Desbats et al., 2015; Fernandez-Ayala et al., 2013; Trevisson, DiMauro, Navas, & Salviati, 2011) . It is recommended to institute treatment as early as possible, since only minimal recovery is possible once damage in critical organs (such as the kidney or the CNS) is established (Acosta et al., 2016) . The non-cerebellar symptoms in our patients were much more difficult to assess because their seizures were already well-controlled by anti-epileptic drugs and the timeframe of the treatment trial did not allow us to perform a repeated neuropsychological assessment.
Nonetheless, we obtained a clinical impression of improvement in both cognitive and behavioral features.
In conclusion, primary CoQ 10 deficiency due to COQ5 mutations is a treatable condition. Response to CoQ10 supplementation might be influenced by the timing of treatment, as we saw in the patients in this study. Early diagnosis by next-generation sequencing in populations showing mild forms of cerebellar ataxia and static encephalomyopathy will be helpful in defining this disorder further, and evaluating the importance of early CoQ10 supplementation.
